Plus Therapeutics is pleased to announce its participation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting and the Melanoma Research Foundation (MRF) Brain Metastases Summit 4.0, taking place on November 9, 2025, in Alexandria, VA. This annual joint event brings together global leaders in immuno-oncology, neuro-oncology, and metastatic cancer research—creating a critical forum for emerging advancements in science and clinical care.
As part of the summit’s dedicated session on leptomeningeal metastases (LM), Andrew Brenner, M.D., Ph.D., Professor of Medicine in the Division of Hematology and Oncology at UT Health San Antonio, will present new insights on Plus Therapeutics’ targeted radiotherapeutic candidate REYOBIQ™ and clinical results from the ongoing ReSPECT-LM clinical trial.
Advancing the Science of LM Treatment Through Precision Radiotherapeutics
Leptomeningeal metastases remain one of the most challenging and life-threatening complications of advanced cancers. Standard treatment options provide limited benefit and often struggle to reach tumor cells dispersed throughout the cerebrospinal fluid (CSF).
Plus Therapeutics is developing REYOBIQ™ (rhenium [186Re] obisbemeda) to address these limitations through a novel, image-guided, intraventricular delivery approach. This strategy is engineered to deliver therapeutic radiation precisely where LM cells reside—inside the CSF compartment—while minimizing exposure to healthy CNS tissue.
Dr. Brenner’s presentation at SITC and the MRF Brain Metastases Summit will highlight:
-
Updated clinical data from the ReSPECT-LM trial
-
Safety and efficacy observations from patients treated to date
-
The potential for REYOBIQ to reshape LM management through precision radiopharmaceutical design
-
Opportunities for integration with next-generation CNS cancer diagnostics, including the CNSide® CSF assay platform
These insights contribute to a growing body of evidence supporting REYOBIQ as a differentiated therapeutic option for patients with LM.
About the ReSPECT-LM Clinical Trial
The ReSPECT-LM trial is an actively enrolling clinical study evaluating REYOBIQ for patients with leptomeningeal metastases originating from solid tumors. The trial uses image-guided administration to deliver localized beta radiation with the goal of improving disease control and quality of life in a patient population with few effective treatment options.
More information on the trial is available here:
https://lnkd.in/gFnhc5Rv
Learn More About Plus Therapeutics’ Presentation at SITC and MRF
Event details and program information can be found here:
https://lnkd.in/gQnqDDYp
As CNS cancers and metastatic diseases continue to demand better therapeutic strategies, Plus Therapeutics remains committed to advancing innovative radiopharmaceutical technologies that address significant unmet medical needs.
Recent Comments